Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Mesa 2021 | Remaining barriers in commercializing advanced therapies

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, addresses issues relating to the commercialization of cell and gene therapies. Major challenges remain in terms of logistics and delivery. Off-the-shelf allogeneic therapies can be given to patients quicker than autologous therapies, as in the case of tabelecleucel, a novel CAR-T cell therapy which can be delivered to patients in three days. He additionally highlights reimbursement issues for these one-off treatments. This interview took place at Meeting on the Mesa 2021.


Pascal Touchon is the Chief Executive Officer of Atara Biotherapeutics, San Francisco, CA and a Board Member of Dantari Pharmaceuticals, Thousand Oaks, CA